Humana (HUM) 주식 개요
는 미국에서 의료 및 특수 보험 상품을 제공합니다. 자세히 보기
HUM Community Fair Values
Create NarrativeSee what 105 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$212.87
FV
91.6% 고평가 내재 할인율8.70%
Revenue growth p.a.
66
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Humana Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$407.78 |
| 52주 최고가 | US$415.00 |
| 52주 최저가 | US$163.11 |
| 베타 | 0.72 |
| 1개월 변동 | 7.24% |
| 3개월 변동 | 103.12% |
| 1년 변동 | 79.99% |
| 3년 변동 | -8.83% |
| 5년 변동 | -12.02% |
| IPO 이후 변동 | 34,105.86% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 09
HUM: Medicare Advantage Rate And Stars Headwinds Will Restrain Margin Recovery
Humana's analyst fair value estimate has moved from $290.08 to $308.33 as analysts factor in higher target prices, supported by views of steadier medical cost trends, recovering Medicare Advantage margins, and a more stable policy backdrop for managed care. Analyst Commentary Recent Street research on Humana reflects a mix of confidence around the reset in Medicare Advantage economics and caution on execution risks over the next few years.
내러티브 업데이트 • Jun 25
HUM: Medicare Advantage Margin Recovery Will Restore Earnings Power And Future Multiple
Humana's fair value estimate has been raised from $371.06 to $441.00 as analysts factor in higher target prices, greater comfort with cost trends, and expectations for a more stable managed care policy backdrop that keeps attention on margin recovery and underlying earnings power. Analyst Commentary Recent research on Humana reflects a clear shift toward more constructive sentiment, with many bullish analysts lifting price targets and, in some cases, upgrading ratings as they reassess earnings power, margin recovery, and the policy backdrop for managed care.Recent updates
내러티브 업데이트 • Jul 09
HUM: Medicare Advantage Rate And Stars Headwinds Will Restrain Margin Recovery
Humana's analyst fair value estimate has moved from $290.08 to $308.33 as analysts factor in higher target prices, supported by views of steadier medical cost trends, recovering Medicare Advantage margins, and a more stable policy backdrop for managed care. Analyst Commentary Recent Street research on Humana reflects a mix of confidence around the reset in Medicare Advantage economics and caution on execution risks over the next few years.내러티브 업데이트 • Jun 25
HUM: Medicare Advantage Margin Recovery Will Restore Earnings Power And Future Multiple
Humana's fair value estimate has been raised from $371.06 to $441.00 as analysts factor in higher target prices, greater comfort with cost trends, and expectations for a more stable managed care policy backdrop that keeps attention on margin recovery and underlying earnings power. Analyst Commentary Recent research on Humana reflects a clear shift toward more constructive sentiment, with many bullish analysts lifting price targets and, in some cases, upgrading ratings as they reassess earnings power, margin recovery, and the policy backdrop for managed care.분석 기사 • Jun 16
Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally
Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation. See our latest analysis for Humana. Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently...내러티브 업데이트 • Jun 08
HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins
Humana's updated analyst price target has moved higher from about $210 to roughly $290, as analysts point to muted medical cost trends, potential Medicare Advantage margin recovery, and company specific Stars improvement as key supports for earnings power. Analyst Commentary Recent research shows a clear reset higher in Humana's valuation framework, with multiple firms lifting price targets and, in some cases, upgrading ratings as they reassess earnings power tied to medical cost trends and Medicare Advantage margins.내러티브 업데이트 • May 25
HUM: Medicare Advantage Margin Recovery Will Support Future Multiple Repricing
Humana's updated analyst price target of about $371, up from roughly $322, reflects analysts' focus on stabilizing managed care trends, expectations around Medicare Advantage margin recovery, and a shift to a slightly higher discount rate and profit margin in the underlying assumptions. Analyst Commentary Recent Street research on Humana centers on how quickly Medicare Advantage margins might stabilize, how medical loss ratios track against company targets, and what that could mean for valuation as managed care trends settle.Seeking Alpha • May 18
Humana: Perhaps The 'Buy The Dip' Thesis Was Right All Along (Rating Upgrade)
Summary Humana Inc. is upgraded to Buy as shares rebound from a >65% decline, supported by improved CMS rate decisions and activist investor involvement. Despite 2026 EPS guidance below Q1 levels, HUM targets a sustainable 3%+ Medicare Advantage margin and long-term earnings growth by 2028. Recent Q1 results exceeded revenue and adjusted EPS expectations, with a favorable medical benefit ratio and affirmed 25% MA membership growth for 2026. Activist pressure and management’s focus on pricing, benefit adjustments, and operational discipline position HUM for a potential return to >$450/share by 2028. Read the full article on Seeking Alpha내러티브 업데이트 • May 03
HUM: Medicare Advantage Margin Execution Will Support Future Multiple Repricing
Humana's updated fair value estimate has moved from $302.11 to $322.19 as analysts adjust price targets higher across multiple firms, citing recent research that reflects revised revenue growth, margin expectations, and a higher assumed future P/E of 14.99. Analyst Commentary Recent Street research around Humana has shifted from sharp cuts earlier in the year to a cluster of higher price targets more recently.내러티브 업데이트 • Apr 19
HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Uncertainty
Humana's updated analyst price target edges slightly lower to about $210, as analysts balance recent target cuts tied to Medicare Advantage margin concerns with more recent upward revisions that reflect adjusted models, a modestly lower discount rate, and a slightly different profit margin and forward P/E outlook. Analyst Commentary Recent Street research on Humana reflects a split view, with some analysts revising price targets higher after updating models, while others remain cautious following earlier target cuts and rating downgrades tied to Medicare Advantage margins and CMS rate decisions.내러티브 업데이트 • Apr 04
HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential
Humana's updated analyst price target has shifted down from $348.00 to about $302.11, as analysts factor in lower target ranges across the Street, a higher discount rate, and cautious views on Medicare Advantage margins and earnings visibility. Analyst Commentary Recent Street research on Humana reflects a broadly cautious stance, with several firms cutting price targets and reassessing Medicare Advantage earnings power.내러티브 업데이트 • Mar 21
HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Headwinds
Humana's updated analyst price target has been trimmed by about $12 to $212.17, as analysts factor in more cautious assumptions around Medicare Advantage margins, earnings guidance, and recent sector wide target cuts following Q4 results and regulatory news. Analyst Commentary Recent research on Humana reflects a clear reset in expectations, with price targets moving lower and ratings clustered around neutral.내러티브 업데이트 • Mar 07
HUM: Medicare Advantage Margin Recovery Will Drive Future Upside Potential
Our updated Humana fair value estimate moves from $287.38 to $223.88, reflecting analysts' lower price targets across the Street as they factor in uncertainty around Medicare Advantage margin improvement, EPS guidance drivers, and the profitability of recent membership growth. Analyst Commentary Recent Street research around Humana has turned more cautious, with multiple firms cutting price targets and some shifting to more neutral stances.
내러티브 업데이트 • Feb 21
HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset
Humana's analyst fair value estimate has been reset from about $199.74 to $146.00. This reflects a broad wave of lower price targets as analysts factor in updated EPS guidance, Medicare Advantage margin uncertainty, and recent model revisions after Q4 results and regulatory developments.내러티브 업데이트 • Feb 07
HUM: Policy And Margin Headwinds Will Shape A Gradual Recovery Path
Narrative Update on Humana The analyst price target for Humana has been reduced by about $18.75. Analysts point to recent downgrades, cautious reactions to CMS rate developments, and more conservative margin assumptions, even as they acknowledge potential longer term sector recovery drivers.분석 기사 • Feb 05
Humana Inc. (NYSE:HUM) Might Not Be As Mispriced As It Looks After Plunging 30%
Humana Inc. ( NYSE:HUM ) shareholders won't be pleased to see that the share price has had a very rough month, dropping...내러티브 업데이트 • Jan 24
HUM: Margin And Policy Uncertainty Will Drive A More Cautious Outlook
Narrative Update Analysts have trimmed their price expectations for Humana, with the updated fair value estimate moving from about US$224 to roughly US$218. This reflects a higher discount rate, more cautious profit margin assumptions, and a lower future P/E multiple, even though modeled revenue growth is higher and recent research views are a mix of supportive and more restrained perspectives.내러티브 업데이트 • Jan 08
HUM: Legal Appeals And Margin Recovery Prospects Will Shape Balanced Outlook
Humana's updated analyst price target has edged down by about $1 to roughly $287. Analysts are balancing slightly higher long term revenue and margin assumptions with mixed ratings that range from Sell to Outperform across recent research.분석 기사 • Dec 19
Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885
Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...내러티브 업데이트 • Dec 14
HUM: Legal Appeals And Star Ratings Will Shape Balanced Outlook Ahead
Analysts have modestly increased Humana's fair value estimate by about $2 to roughly $288, reflecting slightly stronger projected revenue growth and improved earnings visibility, even as they incorporate more conservative sector margin assumptions and ongoing concerns about Medicare Advantage and Medicaid cyclicality. Analyst Commentary Recent Street research paints a mixed picture for Humana, with modest upside to fair value supported by improving earnings visibility, but tempered by meaningful concerns around Medicare Advantage dynamics, contract diversification efforts, and broader managed care cyclicality.분석 기사 • Dec 05
Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885
Humana Inc.'s ( NYSE:HUM ) investors are due to receive a payment of $0.885 per share on 30th of January. This payment...내러티브 업데이트 • Nov 30
HUM: Shares Should Rebound As Legal Efforts Progress On Medicare Bonus Cuts
Humana's analyst price target has been modestly reduced from $288.46 to $286.63. Analysts are factoring in more conservative margin assumptions following recent quarterly results and updated evaluations of the company's revenue growth and profitability outlook.분석 기사 • Nov 16
Humana (NYSE:HUM) Has Announced A Dividend Of $0.885
Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...내러티브 업데이트 • Nov 15
HUM: Confidence Will Increase As Medicare Advantage Star Ratings Recover
Humana's analyst price target has been revised lower by approximately $7 to $288.46. Analysts cite a more cautious outlook on margins and an uneven recovery in Medicare Advantage profitability.분석 기사 • Nov 13
Humana's (NYSE:HUM) Conservative Accounting Might Explain Soft Earnings
Investors were disappointed with the weak earnings posted by Humana Inc. ( NYSE:HUM ). However, our analysis suggests...분석 기사 • Nov 02
Humana (NYSE:HUM) Will Pay A Dividend Of $0.885
The board of Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend on the 30th of January, with investors...내러티브 업데이트 • Nov 01
HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook
Humana's analyst price target increased slightly, rising by approximately $0.83 to $295.38. Analysts cite mixed dynamics in Medicare Advantage star ratings and improving earnings visibility as factors supporting cautious optimism.내러티브 업데이트 • Oct 18
AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery
Humana’s analyst price target increased slightly to $294.54 from $292.87. Analysts cite improved earnings visibility and the stability of Medicare Advantage star ratings as supporting factors for the upward revision.내러티브 업데이트 • Oct 04
AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery
Humana's analyst price target has fallen from approximately $299 to $293 per share, as analysts cite ongoing challenges in Medicare Advantage star ratings and a more cautious growth outlook. This comes despite recent plan diversification efforts.내러티브 업데이트 • Sep 05
AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery
Humana’s modestly higher fair value reflects improving investor sentiment, positive management commentary on future plan positioning, raised earnings guidance, and incremental legislative benefits, offset by some caution around interest rates and policy uncertainty, resulting in the consensus analyst price target rising slightly from $293.05 to $294.86. Analyst Commentary Improved investor sentiment and sector group valuations suggest estimates may have bottomed, with upcoming catalysts including government budget deals, Medicare Advantage and ACA pricing, and star ratings for future plans.분석 기사 • Aug 26
Humana (NYSE:HUM) Has Affirmed Its Dividend Of $0.885
Humana Inc. ( NYSE:HUM ) will pay a dividend of $0.885 on the 31st of October. The dividend yield is 1.2% based on this...분석 기사 • Aug 15
Humana Inc. (NYSE:HUM) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable
NYSE:HUM 1 Year Share Price vs Fair Value Explore Humana's Fair Values from the Community and select yours Humana Inc...Seeking Alpha • Feb 12
Humana Q4 Earnings Review: A Tough Quarter -- And A Rating Downgrade
Summary Humana Inc.'s Q4 and full-year 2024 earnings report shows a 10% revenue increase but significant losses, highlighting major structural issues in its business model. Rising healthcare utilization and insufficient CMS rate increases have severely impacted Humana's profitability, with shares down 50% from their 2023 peak. New management aims to improve efficiency and service quality, but the company's future hinges on CMS rate decisions and star-rating litigation outcomes. Given the high uncertainty and potential for further losses, I recommend a “Hold” on HUM shares unless willing to take substantial risk. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Humana's Growth Vs. Rising Costs: Why It's A Hold For Cautious Investors
Summary Humana is doubling down on Medicare Advantage and healthcare services while cutting less profitable areas. Higher costs and lower profit margins are putting pressure on the business right now. Medicare Advantage growth and expanding healthcare services show long-term potential. Regulatory changes and restructuring costs could make the next couple of years bumpy. The stock looks fairly priced, so holding for now seems like the best move. Read the full article on Seeking Alpha주주 수익률
| HUM | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | 2.9% | 0.09% | 0.2% |
| 1Y | 80.0% | 35.3% | 19.6% |
수익률 대 산업: HUM은 지난 1년 동안 35.3%의 수익을 기록한 US Healthcare 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: HUM은 지난 1년 동안 19.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| HUM volatility | |
|---|---|
| HUM Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: HUM는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: HUM의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1961 | 67,060 | Jim Rechtin | www.humana.com |
는 미국에서 의료 및 특수 보험 상품을 제공합니다. 이 회사는 보험과 센터웰의 두 부문으로 운영됩니다. 보험 부문에서는 웰니스 프로그램, 만성 치료 관리 및 치료 조정을 포함한 건강 보험 혜택, 개인용 메디케어 독립형 처방약 상품(PDP), 그룹 메디케어 어드밴티지 및 메디케어 독립형 PDP, 메디케어 보조제, 치과, 시력, 생명 및 장애로 구성된 전문 및 보조 보험, 현역 및 퇴역 군인 및 부양가족, 약국 혜택 관리자를 위한 건강 관리 서비스를 제공하는 행정 서비스 등을 제공합니다.
Humana Inc. 기초 지표 요약
| HUM 기초 통계 | |
|---|---|
| 시가총액 | US$48.84b |
| 순이익 (TTM) | US$1.13b |
| 매출 (TTM) | US$137.20b |
43.3x
주가수익비율(P/E)0.4x
주가매출비율(P/S)HUM는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| HUM 손익계산서 (TTM) | |
|---|---|
| 매출 | US$137.20b |
| 매출원가 | US$117.98b |
| 총이익 | US$19.22b |
| 기타 비용 | US$18.09b |
| 순이익 | US$1.13b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 29, 2026
| 주당순이익(EPS) | 9.41 |
| 총이익률 | 14.01% |
| 순이익률 | 0.82% |
| 부채/자본 비율 | 77.1% |
HUM의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Humana 배당 일정 | |
|---|---|
| 배당락일 | Jun 26 2026 |
| 배당 지급일 | Jul 31 2026 |
| 배당락일까지 남은 일수 | 20 days |
| 배당 지급일까지 남은 일수 | 15 days |
HUM는 안정적으로 배당을 지급합니까?
HUM 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/15 21:50 |
| 종가 | 2026/07/15 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Humana Inc.는 37명의 분석가가 다루고 있습니다. 이 중 21명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |